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C

reated on July 1, 2000, the Department of Managed Health Care (DMHC)
regulates the managed care industry in California. The creation of DMHC
resulted from Governor Gray Davis’s approval of AB 78 (Gallegos) (Chapter
525, Statutes of 1999), a bill that reformed the regulation of managed care in

the state. DMHC is created in Health and Safety Code section 1341; DMHC’s regulations are
codified in Title 28 of the California Code of Regulations (CCR).
DMHC administers the Knox-Keene Health Care Service Plan Act of 1975, Health and
Safety Code section 1340 et seq., which is intended to promote the delivery of health and medical
care to Californians who enroll in services provided by a health care service plan. A “health care
service plan” (health plan)—more commonly known as a health maintenance organization (HMO)
or managed care organization (MCO)—is defined broadly as any person who undertakes to arrange
for the provision of health care services to enrollees, or to pay for or reimburse any part of the cost
for those services, in return for a prepaid or periodic charge paid by or on behalf of the enrollees.
In Health and Safety Code section 1342, the legislature has expressly instructed the
Department Director to ensure the continued role of the professional as the determiner of the
patient’s health needs; ensure that enrollees 1 are educated and informed of the benefits and services
available in increase consumer choice in the healthcare market; and promote effective
representation of the interests of enrollees, including ensuring the best possible health care at the

1

Enrollees, Members, and Subscribers are referred to herein as “enrollee(s).”
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lowest possible cost by transferring financial risk of health care from patients to providers. The
Department Director must also prosecute individuals and/or health plans who engage in fraud or
misrepresent or deceive consumers; and ensure the financial stability of health plans through
proper regulation health care must be accessible to enrollees and rendered in a manner to provide
continuity of care, which includes a grievance process that is expeditious and thoroughly reviewed
by DMHC.
The Director of DMHC is appointed by, and serves at the pleasure of, the Governor. The
Department’s staff of attorneys, financial examiners, health plan analysts, physicians, health care
professionals, consumer service representatives, and support staff assist the DMHC Director in
licensing and regulating more than 130 health plans in California. Licensed health plans include
HMOs and other full-service health plans, as well as several categories of specialized health plans
such as prepaid dental, vision, mental health, chiropractic, and pharmacy plans. DMHC-licensed
health plans provide health care services to approximately 26 million California enrollees.
Created in Health and Safety Code section 1374.30 et seq., DMHC’s independent medical
review (IMR) system allows health plan enrollees to seek an independent review when medical
services are denied, delayed, or otherwise limited by a plan or one of its contracting providers,
based on a finding that the service is not medically necessary or appropriate. The independent
reviews are conducted by expert medical organizations that are independent of the health plans
and certified by an accrediting organization. An IMR determination is binding on the health plan,
and the Department will enforce it.
SB 260 (Speier) (Chapter 529, Statutes of 1999), added section 1347.15 to the Health and
Safety Code to create the Financial Solvency Standards Board (FSSB). Comprised of the DMHC
Director and seven members appointed by the Director, FSSB periodically monitors and reports
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on the implementation and results of those requirements and standards, and reviews proposed
regulatory changes. FSSB advises the DMHC Director on matters of financial solvency affecting
the delivery of health care services. FSSB develops and recommends financial solvency
requirements and standards relating to plan operations.
DMHC houses the Help Center, which is open 24 hours a day, 365 days a year, and
functions in many languages to help consumers who experience problems with their health plan.
The Help Center educates consumers about their health care rights; resolves consumer complaints;
helps consumers navigate and understand their coverage; and ensures access to appropriate health
care services. The DMHC Help Center provides direct assistance to health care consumers through
a call center and online access. DMHC is funded by assessments on its regulated health plans.

MAJOR PROJECTS
DMHC Rulemaking
The following are status updates on recent rulemaking proceedings that DMHC has
initiated, some of which were covered in more detail in Volume 24, Number 1 of the California
Regulatory Law Reporter [24:1 CRLR 20–26]:
♦ General Licensure Requirements. On November 30, 2018, DMHC published a notice
of 4th comment period to add section 1300.49, Title 28 of the CCR, which attempted to clarify the
Knox-Keene Act’s definition of a “health care service plan” that requires licensure by DMHC. The
new regulation would have defined “health care service plan” to include an entity that takes on
global risk (both institutional and professional risk) for services provided to health plan enrollees,
would have set forth requirements for a restricted health plan license, as well as standards for
obtaining an exemption from licensing requirements. The modified text is the result of information
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received during the third comment period and the information in the Notice of Disapproval issued
by the Office of Administrative Law (OAL) on October 8, 2018, and in its Decision of Regulatory
Action dated October 15, 2018, which is set forth in the proposed language. [24:1 CRLR 20–21]
According to the final statement of reasons and its attached addendum, the proposed
regulation updates the Economic Impact Analysis by providing clarity around licensure
requirements of restricted health care service plans; specifies existing state law for health care
service plans; simplifies the information the Director will consider when determining whether an
exemption request will be granted; and identifies a process for an exemption request from DMHC.
On March 5, 2019, OAL approved the final text of the general licensure requirements to
be effective July 1, 2019.
♦ Cancellations, Rescissions, and Non-renewals of Health Plan Enrollment,
Subscription, or Contract. On December 28, 2018, DMHC published a notice of 2nd comment
period to delete sections 1300.65, 1300.65.1, 1300.65.2, and add sections 1300.65, 1300.65.1,
1300.65.2, 1300.65.3, 1300.65.4, 1300.65.5, Title 28 of the CCR, to clarify and interpret the
rights and responsibilities of plans, providers, and enrollees prior to, during, and following
cancellations, rescissions, or non-renewals of an enrollee’s health care coverage. The modified
text is the result of information received during the initial comment period, which is set forth in
the proposed language.
On February 28, 2019, DMHC published a notice of 3rd comment period affecting the
same sections outlined in the prior paragraph. The revised language responds to public comments
to clarify and keep consistency in the relevant terms throughout the regulation.
On June 22, 2018, DMHC originally proposed amendments to the Cancellations,
Rescissions, and Nonrenewals regulations, in order to impose limitations on the cancellation,
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rescission, and nonrenewal of health care service plan contracts, and provide enrollees,
subscribers, and group contract holders with a right to file a grievance with DMHC in certain
situations consistent with federal law under the Patient Protection and Affordable Care Act
(PPACA). [24:1 CRLR 22–23]
DMHC did not schedule a public hearing on these proposed regulatory changes, but
accepted written comments until March 15, 2019. At this writing, DMHC is reviewing the
comments received during the comment period and is preparing modified text of the proposed
changes.
♦ Financial Solvency of Risk-Bearing Organizations (RBOs). DMHC does not directly
regulate RBOs; however, it is authorized to regulate health plan contracts with RBOs. Hence, on
May 25, 2018, DMHC originally proposed amendments to the Financial Solvency of RBOs
regulation in a notice of proposed rulemaking. [24:1 CRLR 23–25] On November 15, 2018,
DMHC published a notice of 3rd comment period to amend sections 1300.75.4, 1300.75.4.1,
1300.75.4.2, 1300.75.4.5, 1300.75.4.7, 1300.75.4.8, and 1300.76, Title 28 of the CCR, for an
additional 15-day public comment period that ended on December 4, 2018. The third revision of
the modified text addresses public comments received during the second comment period.
On January 4, 2019, DMHC published a notice of 4th comment period to continue
amending the same sections outlined in the prior paragraph, for an additional 15-day public
comment period that ended on January 22, 2019. The fourth revision of the text is a result of the
information received during the third comment period, which is set forth in the proposed language,
which is the final text submitted to OAL. According to the final statement of reasons, the proposed
regulations represent the cumulative effort of DMHC to adopt rules and regulations to implement
a process for reviewing and grading the financial solvency of RBOs. This includes clarifying the
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financial information required from RBOs to assist in DMHC’s review, including when DMHC
conducts audits and when DMHC processes corrective action plans for RBOs with solvency
problems. The regulations cover disclosure of relevant information from health plans to RBOs to
enable the organization to be informed regarding the risks assumed under the parties’ contract. The
regulations also cover how health plans and RBOs file periodic reports to DMHC, ensuring
confidentiality of consumers.
At its April 10, 2019 teleconference meeting, DMHC voted to adopt the final text of the
regulatory action, until such time as OAL approves the regulatory action through the formal
rulemaking process. A hearing on the proposed regulations is set for May 6, 2019.

Standard Prescription Drug Formulary Template
On February 20, 2019, DMHC published a notice of 2nd comment period to add section
1300.67.205, Title 28 of the CCR, a proposed regulatory action to set minimum standards for its
drug formulary. The modified text is the result of comments received during the initial 45-day
comment period that ended on November 13, 2018, and the public hearing held on November 13,
2018. DMHC accepted written comments relating to the modified text until March 7, 2019.
Following the second comment period, DMHC released the revised text of the proposed regulation.
At the time of this writing, DMHC had not scheduled a public hearing on the proposed changes
and was reviewing additional comments.
DMHC also released an addendum to the Notice of Rulemaking and the Initial Statement
of Reasons noticed on September 28, 2018. [24:1 CRLR 21–22] In the addendum, DMHC updated
its Summary of Fiscal Impact contained in its initial Notice of Rulemaking, to now include the
determination that there will be a fiscal impact to Medi-Cal only managed care plans to comply
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with the requirements of the regulation. The estimated fiscal amount to upgrade computer systems
is $13,041 per health plan, bringing the total fiscal impact to $143,452. At this writing, DMHC
has not taken further action on the regulation.

DMHC Releases 2017 Timely Access Report
On December 19, 2018, DMHC published the Timely Access Report for Measurement
Year (MY) 2017. The Timely Access Regulation, which became effective in 2010, “requires that
health plan networks be sufficient to meet a set of standards, which include specific timeframes
under which enrollees must be able to obtain care.” The Timely Access Report summarizes
provider appointment availability data that health plans submitted to DMHC for Measurement
Year 2017. The charts within the report show provider responses to appointment availability
requests.
According to the report, DMHC required full-service health and behavioral health plans to
utilize external vendors to validate the health plans’ Timely Access data prior to submitting them
to DMHC. DMHC found some data errors in MY 2017 data that health plans were unable to
correct. Although these errors limit some of the possible data representations, DMHC was able to
compare MY 2017 data across health plans at a more granular level than for previously reported
years. As a result, DMHC expanded the number of charts in the report and displayed data by type
of health plan for the first time: Commercial; Individual/Family; and Medi-Cal.
Regarding 2017 data, some health plans continued to have issues with following the
mandatory methodology, completing all of the required surveys, and achieving an acceptable
statistical sample of surveyed providers. According to DMHC, ensuring that health plans provide
timely access to health care services is one of its highest priorities and DMHC continues to work
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with stakeholders, including health plans, providers, associations and consumer advocates to refine
the provider survey methodology and develop an acceptable rate of compliance for provider
appointment wait times. Furthermore, DMHC is taking the necessary steps to have mandatory
methodologies for measuring compliance with the timely access standards and the acceptable rate
of compliance included in regulation so that compliance results are comparable year over year.
Key Survey Findings for Full-Service Health Plans. The percentage of all surveyed
providers who had appointments available within the wait time standards (urgent and non-urgent)
ranged from a high of 99% to a low of 63% (Chart 1). For non-urgent appointments, the percentage
of all surveyed providers who had appointments available within the wait time standards ranged
from a high of 99% to a low of 70% (Chart 5). For urgent appointments, the percentage of all
surveyed providers who had appointments available within the wait time standards ranged from a
high of 99% to a low of 52% (Chart 9).
Key Survey Findings for Behavioral Health Plans. The percentage of all surveyed
providers who had appointments available within the wait time standards (urgent and non-urgent)
ranged from a high of 83% to a low of 64% (Chart 13). For non-urgent appointments, the
percentage of all surveyed providers who had appointments available within the wait time
standards ranged from a high of 87% to a low of 71% (Chart 17). For urgent appointments, the
percentage of all surveyed providers who had appointments available within the wait time
standards ranged from a high of 80% to a low of 57% percent (Chart 21).
Key Audit Findings for Full-Service Health Plan, Kaiser Permanente. The percentage of
all audited providers meeting appointment wait time standards across all provider types and
appointment types (urgent and non-urgent) was 92% (Chart 25). The percentage of all audited

California Regulatory Law Reporter ♦ Volume 24, No. 2 (Spring 2019) ♦
Covers October 16, 2018 – April 15, 2019

18

providers meeting non-urgent appointment standards was 91% (Chart 29). The percentage of all
audited providers meeting urgent appointment standards was 98% (Chart 33).

DMHC Releases 2017 Prescription Drug Cost
Transparency Report
Despite undecided legal challenges to the constitutionality of the 2017 legislation [see
LITIGATION], on December 27, 2018, DMHC released its Prescription Drug Cost Transparency
Report (SB 17). SB 17 (Hernandez) (Chapter 603, Statutes of 2017), as codified in Health and
Safety Code section 1367.243, requires health plans that file rate information with DMHC to
annually report specific information related to the costs of covered prescription drugs. Prescription
drug data was submitted by 25 health plans for measurement year 2017. DMHC states that it will
continue to collect and report on the data required by SB 17, which will enable the public to
understand how prescription drugs impact health care premiums over time.
This report looks at the impact of the cost of prescription drugs on health plan premiums.
According to the report, DMHC considered the total volume of prescription drugs prescribed by
health plans and the total cost paid by health plans for these drugs, on both an aggregate spending
level and a per member per month basis (PMPM). DMHC also analyzed how the 25 most
frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-overyear increase in total annual spending impacted premiums.
Key Findings. According to the report, health plans paid nearly $8.7 billion for prescription
drugs in 2017. Prescription drugs accounted for 13.1% of total health plan premiums. Health plans’
prescription drug costs increased by 5% in 2017, whereas medical expenses increased by 5.9%.
Overall, total health plan premiums increased 4.8% from 2016 to 2017. Manufacturer drug rebates
equaled approximately $915 million, or about 10.5%, of the $8.7 billion spent on prescription
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drugs. While specialty drugs accounted for only 1.6% of all prescription drugs, they accounted for
over half (51.5%) of total annual spending on prescription drugs. Generic drugs accounted for
nearly 90% (87.8%) of all prescribed drugs but only 23.6% of the total annual spending on
prescription drugs. Brand name drugs accounted for 10.6% of prescriptions and constituted 24.8%
of the total annual spending on prescription drugs. The 25 Most Frequently Prescribed Drugs
represented 47.7% of all drugs prescribed and approximately 42.8% of the total annual spending
on prescription drugs. For the 25 Most Frequently Prescribed Drugs, enrollees paid approximately
3% of the cost of specialty drugs and over half (56.6%) the cost of generic drugs. Overall, plans
paid over 90% of the cost of the 25 Most Costly Drugs across the three categories (generic, brand
name, and specialty).
As reported by DMHC, the impact of prescription drug costs on health plan premiums is
significant. Health plans paid nearly $8.7 billion for prescription drugs in 2017, which accounted
for 13.1% of the total health plan premium in 2017. This amount is primarily related to the cost of
specialty drugs. Overall, specialty drugs accounted for just over 1% of the total number of drugs
prescribed, and represented over half of the health plans’ total annual spending on prescription
drugs. Generic drugs made up nearly 90% at of all the drugs prescribed in 2017 but represented
only about one-quarter of total annual spending on prescription drugs.

Recent Enforcement Actions
Following are recent enforcement actions taken by DMHC:
♦ DMHC Approves Optum’s Acquisition of DaVita. On November 28, 2018, DMHC

approved Optum, Inc.’s acquisition of DaVita Health Plan of California, as contained in a
document setting forth the conditions of the merger. DMHC’s approval includes several conditions
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that will protect enrollees and support behavioral health services. Optum and DaVita agree to not
increase premiums as a result of acquisition costs, and keep premium rate increases to a minimum.
The plans also agree to invest at least $58 million in California as follows: (1) $40 million in
philanthropic activities in California; (2) $10 million to one or more areas that include support for
scholarships through the United Health Foundation Diverse Scholars Initiative, medical grants for
California families, investments to help address social determinants of health and other health and
wellness initiatives; and (3) $8 million to support behavioral health services by providing
scholarships to those seeking to become a psychiatrist or psychiatric nurse practitioner in the field
of Child and Adolescent psychiatry. The health plans will also support activities and implement
programs to address the opioid crisis. This includes educating providers on substance abuse
detection and prescribing naloxone and buprenorphine.
According to DMHC Director Rouillard, there has been rapid consolidation in the health
care industry, including health plan mergers, and “[a]s the primary state regulator of health plans,
[DMHC’s] job is to protect the health care rights of impacted enrollees and ensure a stable health
care delivery system.” In response to DaVita’s notice of the proposed acquisition by Optum in
early 2018, DMHC conducted a comprehensive review of the transaction to ensure compliance
with the Knox-Keene Act. DMHC examined both parties’ organization and corporate structures,
administrative capacity changes, health care delivery system changes, product or subscriber
changes, the effect of the transaction on the financial viability of DHMC licensed plans, the
financing for the transaction, and its impact on consumers. DMHC’s Financial Solvency Standards
Board (FSSB) held a public meeting on the acquisition back in April, 2018. At the meeting,
Director Rouillard reiterated that the Department’s primary focus in reviewing these mergers is to
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ensure compliance with the strong consumer protections and financial solvency requirements of
the Knox-Keene Act.
♦ LA Care Grievance Process Violations Result in $280,000 Fine. On November 6, 2018,

DMHC announced it would fine LA Care $280,000 for systemic grievance process violations.
DMHC Director Rouillard stated that health plans are required by law to have a grievance process
in place to resolve consumers’ complaints and ensure access to appropriate care. DMHC found
that “LA Care failed to comply with laws surrounding the grievance and appeals system and must
correct their deficiencies to ensure consumers know their health care rights and how to act on
them.”
According to DMHC, this enforcement action is a result of 21 cases involving 63 consumer
grievance violations that occurred during 2014 through 2017. In these cases, LA Care deprived
enrollees of their rights to medical care in that it failed to identify, timely process, and resolve
consumer grievances. Additionally, LA Care did not comply with statutory timeframes to provide
DMHC information during investigation of member complaints. The plan has acknowledged its
failure to comply with the law, and DMHC has determined that an administrative penalty and
Corrective Action Plan are warranted. The corrective actions include employee training and
increased oversight of the grievance and appeals system.

DMHC Approves CVS-Aetna Merger
On November 15, 2018, DMHC Director Rouillard issued a statement of approval for the
CVS-Aetna merger. DMHC placed conditions on the approval of the merger. CVS and Aetna
agreed to not increase premiums as a result of acquisition costs and to keep premium rate increases
to a minimum. The plans also agree to invest nearly $240 million in California’s health care
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delivery system. As part of DMHC’s conditions, CVS and Aetna confirmed the sale of Aetna’s
Medicare Part D Individual Prescription Drug business to WellCare in compliance with the
conditional approval by the U.S. Department of Justice. Additionally, until the divestiture is
completed, CVS and Aetna will guarantee Aetna’s Medicare Part D Individual Prescription Drug
business in California continues to be a viable and competitive plan for 2019.
On April 5, 2019, Judge Richard Leon of the U.S. District Court for the District of
Columbia heard argument from parties as to what, if any, witnesses should be called at any hearing
on the Government’s Motion for Entry of Final Judgment. Pending Judge Leon’s approval, CVS
agreed to temporarily allow Aetna to independently make critical product, pricing and personnel
decisions.
Prior editions of the Reporter have covered the proposed acquisition in January of 2018,
through DMHC’s examination of CVS’ and Aetna’s structures, including a public hearing in May
of 2018. [23:2 CRLR 18–19] On October 10, 2018, the Department of Justice conditionally
approved the CVS-Aetna merger. [24:1 CRLR 27–28]

DMHC Approves Cigna-Express Scripts Merger
On December 13, 2018, the Cigna-Express merger was approved by the New York
Department of Financial Services and DMHC. Further, the New York Superintendent, Maria
Vullo, cancelled the hearing that was scheduled for January 10, 2019 after receiving commitments
from the applicants to conditions of approval that address anti-competitive concerns.
On December 13, 2018, Director of DMHC Rouillard issued a statement of approval for
the Cigna-Express acquisition. DMHC placed conditions on the approval of the merger, including
agreement to not increase premiums as a result of acquisition costs and to keep premium rate
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increases to a minimum. Both companies will also invest over $60 million in California healthcare
initiatives, including the opioid crisis and healthcare delivery.
The U.S. Department of Justice approved the Cigna-Express acquisition in September of
2018. [24:1 CRLR 28–29]

LEGISLATION
AB 1802 (Committee on Health), as amended April 11, 2019, would amend sections
1358.20, 1368.015, 1368.02, 1371, and 1373.65 of the Health and Safety Code, relating to health
care service plans. The bill would clarify that the obligation of a health plan to comply with claims
reimbursement obligations is not deemed to be waived if the plan requires its medical groups,
independent practice associations, or other contracting entities to pay claims for covered services.
According to the Committee on Health, this bill reverts language back to its original statutory
language to apply to all health plans and updates DMHC telephone and internet website addresses
in specified materials. [A. Health]
AB 1174 (Wood), as amended March 25, 2019, would add sections 1341.46 and 1371.32
to the Health and Safety Code, relating to anesthesia services. According to the author, this bill
would ensure that health plans and health insurers have a contractual relationship with
anesthesiologists such that enrollees will have access to these types of providers at contracted
facilities. This bill would require a health plan to notify DMHC before the expiration or termination
of an anesthesia services contract. This bill would also require DMHC to make a finding that the
health plan have contracts in place that meet the following: 1) the health plan has a contract with
at least one individual health professional who is licensed by the state to deliver or furnish
anesthesia services (individual health professional) for each of its contracted facilities; and 2) an
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enrollee requiring anesthesia services has access to contracted individual health professional at all
times and for all procedures at each of the contracted facilities. [A. Appr]
AB 651 (Grayson), as amended April 8, 2019, would add section 1371.55 to the Health
and Safety Code, relating to air ambulance services. This bill would require a health plan contract
to provide that if an enrollee receives covered services from a noncontracting air ambulance
provider, the individual would pay no more than the same cost sharing that the individual would
pay for the same covered services received from a contracting air ambulance provider, as specified.
Among other things this bill would, commencing January 1, 2020, and to the extent that federal
financial participation is available and federal approvals have been obtained, require the
department to set and maintain the Medi-Cal fee rate for air ambulance services provided by either
fixed or rotary wing aircraft that is equal to a percentage of the rural Medicare rates for those
services. This would be a rate increase for air ambulance providers that, according to the sponsor,
is necessary to maintain adequate coverage of services across the state. [A. Health]
AB 1611 (Chiu), as introduced February 22, 2019, would amend section 1317.2a of, and
add sections 1317.11, 1317.12, 1371.6, 1371.7, and 1385.035 to, the Health and Safety Code,
relating to hospital service costs. This bill would prohibit a hospital from charging more than the
greater of the average contracted rate or 150% of the amount Medicare reimburses on a fee for
service basis for the same or similar hospital services in the general geographic region in which
the services were rendered, as specified, for emergency care or post-stabilization care. This bill
would also require a health plan contract amended or renewed on or after January 1, 2020, to
provide that if an enrollee receives covered services from a noncontracting hospital, the enrollee
is prohibited from paying more than the same cost sharing that the enrollee would pay for the same
covered services received from a contracting hospital. [A. Health]
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AB 1670 (Holden), as amended March 18, 2019, would add section 1371.85 to the Health
and Safety Code, relating to health care coverage. This bill would authorize a provider that
contracts with a health plan to bill an enrollee for a service that is not a covered benefit if the
enrollee consents in writing and that written consent meets specified criteria. The bill would
require a contracting provider to provide an enrollee with a written estimate of the person’s total
cost, based on the standard rate the provider would charge for the service, if the service sought is
not a covered benefit under the person’s health plan. The bill would require these documents to be
in the language spoken by the enrollee as specified. A willful violation of the bill’s requirements
relative to health plans would be a crime. [A. Health]
AB 744 (Aguiar-Curry), as introduced February 19, 2019, would amend section 2290.5
of the Business and Professions Code, and amend section 1374.13 of, and add section 1374.14 to
the Health and Safety Code, relating to health care coverage. This bill would require a contract
between a health plan and a healthcare provider to specify that the health plan reimburse a
healthcare provider for the diagnosis, consultation, or treatment of an enrollee, delivered through
telehealth services on the same basis and to the same extent that the health plan is responsible for
reimbursement for the same service through in-person diagnosis, consultation, or treatment. [A.
Health]
AB 954 (Wood), as amended March 27, 2019, would add section 1374.193 to the Health
and Safety Code, relating to dental services. According to the author, network leasing
arrangements present numerous problems for dentists and their patients because plans that lease
or purchase networks do not have any responsibility to be transparent about which fee schedules
are in effect for their patients. To address the need for transparency, the bill would authorize a
health plan that issues, sells, renews, or offers a contract covering dental services to grant third
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party access to a provider network contract entered into, amended, or renewed on or after January
1, 2020, or access to services or discounts provided pursuant to that provider network contract if
certain criteria are met. [A. Appr]
AB 767 (Wicks), as amended April 9, 2019, would amend section 1374.55 of the Health
and Safety Code, relating to infertility. Requires every health plan contract policy that is issued,
amended, or renewed on or after January 1, 2020, to provide coverage for in vitro fertilization
(IVF), as a treatment of infertility, and mature oocyte cryopreservation (OC). This bill would delete
the exemption for religiously affiliated employers and health plans, from the requirements relating
to coverage for the treatment of infertility, thereby imposing these requirements on these
employers and plans. This bill would also delete the requirement that a health plan contract provide
infertility treatment under agreed upon terms that are communicated to all group contractholders
and prospective group contractholders. [A. Health]
SB 600 (Portantino), as introduced February 22, 2019, would add section 1374.551 to the
Health and Safety Code, relating to fertility preservation. This bill would clarify that a health plan
contract that covers hospital, medical, or surgical expenses include coverage for standard fertility
preservation services when a medically necessary treatment may cause infertility to an enrollee.
This bill would also prohibit a health plan from denying coverage of standard fertility preservation
services based on medical necessity of an enrollee’s treatment plan, as specified. As outlined in
the Bill Analysis, “DMHC has initiated enforcement action, and DMHC no longer approves plan
documentation that purports to exclude medically necessary fertility preservation. DMHC has
communicated this to health plans and has conducted individual plan-by-plan conferences to
explain DMHC’s position and expectation for compliance.” [S. Health]
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SB 163 (Portantino), as amended April 9, 2019, would amend section 1374.73 of the
Health and Safety Code, to expand the definition of behavioral health treatment (BHT) and expand
the provider qualifications to include more provider types that can provide BHT under the mandate
that health plans and insurers cover BHT for pervasive developmental disorder or autism. The bill
would prohibit the setting, location, or time of treatment recommended by a qualified autism
services provider from being used as the only reason to deny or reduce coverage for medically
necessary services, and requires the setting be consistent with the standard of care for BHT. This
bill would also require the intervention plan designed by the qualified autism service provider,
when clinically appropriate, to include parent or caregiver participation that is individualized to
the patient and takes into account the ability of the parent or caregiver to participate in therapy
sessions and other recommended activities. Notably, the bill would bring health plans in the MediCal program into compliance with the Mental Health Parity and Addiction Equity Act of 2008
(MHPAEA). [S. HumanS]
SB 11 (Beall), as introduced December 3, 2018, would add sections 1374.77 and 1374.78
to the Health and Safety Code, to require a health plan to submit an annual report to DMHC,
certifying compliance with state and federal mental health parity laws, as specified. The bill would
require DMHC to review the reports submitted by health plans to ensure compliance with relevant
laws, and would require DMHC to make the reports and the results of the reviews available
publicly, including posting on its website. The bill would also require the California State Auditor
to review DMHC and the Department of Insurance’s implementation of this bill and report its
findings to the Legislature. The addition of section 1374.78 would prohibit prior authorization or
step therapy requirements on any prescription medication approved by the federal Food and Drug
Administration for the treatment of substance use disorders. [S. Health]
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AB 731 (Kalra), as amended March 20, 2019, would amend sections 1385.01, 1385.02,
1385.03, and 1385.07 of the Health and Safety Code, relating to DMHC’s rate review of health
plans. According to the author, “[m]any [consumers] are struggling with ever rising co-pays and
health insurance premiums that have risen 249% since 2002, more than six times the increase in
the state’s overall inflation.” This bill would expand the existing requirement—that health plans
offering a contract or policy in the individual or small group market file specified information with
DMHC—to apply to large group health plan contracts. The bill would require a plan to disclose
specified information by geographic region, including annual medical trend factor assumptions by
aggregate benefit category and the top 25 procedures in each benefit category. This bill would also
require a health plan that fails to provide all the information required, to be determined an
unjustified rate. To effectuate its purpose, the bill would eliminate confidentiality protections for
contracted rates between a health plan and a large group. [A. Appr]
AB 1309 (Bauer-Kahan), as introduced February 22, 2019, would add section 1399.848
to the Health and Safety Code, to require a health plan, for policy years beginning on or after
January 1, 2020, to provide a special enrollment period to allow individuals to enroll in individual
health benefits plans through the Exchange from December 16 of the preceding calendar year, to
January 31 of the benefit year. The bill would also require, for health plans offered outside of the
Exchange, that the annual open enrollment period for policy years beginning on or after January
1, 2020, extend from October 15 of the preceding calendar year, to January 31 of the benefit year.
[A. Appr]
SB 159 (Weiner), as amended April 11, 2019, would add section 1342.74 to the Health
and Safety Code, to preclude health plans from requiring a prior authorization or step therapy for
combination antiretroviral drug treatments that are medically necessary for the prevention of
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AIDS/HIV, including pre-exposure prophylaxis or post-exposure prophylaxis. This bill would also
require Medi-Cal to reimburse pharmacies for initiating and furnishing pre-exposure prophylaxis
or post-exposure prophylaxis, and permits a pharmacist to furnish these treatments in accordance
with protocols established by the bill. According to the author, allowing pharmacists to furnish
these treatments without a prescription “will expand access, help increase the number of
individuals who use these HIV preventatives, and will help California achieve its goal to end new
HIV infections.” [S. Health]
AB 1249 (Maienschein), as amended March 18, 2019, would add and repeal section
1343.3 to the Health and Safety Code, to require the DMHC Director, by May 1, 2020, to authorize
two pilot programs, one in northern California and one in southern California. The purpose of the
pilot programs is to demonstrate the control of costs for health care services and the improvement
of health outcomes and quality of service when compared against a sole fee-for-service provider
reimbursement model. Each pilot program would be conducted under the voluntary employees’
beneficiary association (VEBA) with more than 100,000 enrollees. The bill would further require
each health care provider participating in a pilot program to report to DMHC with information
regarding cost savings and clinical patient outcomes. New section 1343.3 would require the
DMHC to report those findings to the legislature by June 1, 2026. [A. Health]
SB 612 (Pan), as introduced on February 22, 2019, would add section 1348.7 to the Health
and Safety Code, to require health plans, health insurers, and medical groups, on or before January
1, 2021, to annually report to the Office of Statewide Health Planning and Development (OSHPD)
in its participation in a list of health care programs and activities. New section 1348.7 would create
requirements for the data that needs to be included, such as detailed descriptions of enrollees,
demographic profiles, numbers and types of participating providers, lengths of participation of
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enrollees, lengths of carrier participation, and performance measures and outcomes. According to
the author, “[t]his bill provides baseline data to policymakers, purchasers, and the public on the
extent to which health plans, health insurers, and medical groups are participating in activities that
provide high quality care and improve outcomes for Californians with chronic disease.” [S. Appr]
SB 129 (Pan), as amended on February 26, 2019, would amend section 1348.95 of the
Health and Safety Code, to require health plans and insurers to annually report enrollment data for
products sold inside and outside of Covered California, any other business lines, and multiple
employer welfare arrangements. New section 1348.95 would require DMHC to publicly report
annual enrollment data no later than April 15 of each year. According to the author, this bill is
necessary to update the annual health plan and insurer enrollment reporting requirements that are
required under the Affordable Care Act. [S. Appr]
SB 406 (Pan), as introduced on February 20, 2019, would amend section 1348.96 of the
Health and Safety Code, to require DMHC (and the Department of Insurance) to each prepare, in
coordination with the other department, an annual summary report that describes the impact of the
risk adjustment program on premium rates in the state. The bill would also require the reports to
be posted on the departments’ respective public websites no later than seven months after the risk
adjustment year. The federal Patient Protection and Affordable Care Act (PPACA), which enacted
various health care coverage market reforms, requires a state, using criteria and methods developed
by the United States Secretary of Health and Human Services, to implement a risk adjustment
program under which a charge is assessed on low actuarial risk plans and a payment is made to
high actuarial risk plans. This bill effectuates the federal legislation. [S. Health]
SB 407 (Monning), as amended on March 28, 2019, would amend sections 1358.11 and
1358.91 of the Health and Safety Code, to extend the Medicare supplement annual open enrollment
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period 30 additional days (for a total of 60 days or more), commencing with the individual’s
birthday. The bill eliminates a restriction that an individual may only purchase coverage during
the annual open enrollment period under specified circumstances, and allowing an individual to
choose any Medicare supplement coverage during the annual open enrollment period. Amended
section 1358.91 would require an issuer of a Medicare supplemental contract with new or
innovative benefits, which is advertised, solicited, or issued for delivery in California on or after
January 1, 2020, to offer the new or innovative benefits only as a rider to the Medicare
supplemental contract, thus creating guaranteed renewability for consumers. [S. Health]
SB 784 (Pan), as introduced on March 7, 2019, would amend sections 1358.91 and 1358.11
of, and add section 1358.92, to the Health and Safety Code, to make conforming changes in
California law to the requirements and standards that apply to Medicare supplement contracts and
policies, for the purpose of complying with the federal laws affecting contracts delivered or issued
after January 1, 2020. This bill contains an urgency clause to ensure that the provisions of the bill
go into immediate effect upon enactment. Supporters of this bill argue that it makes necessary
amendments to California’s laws governing Medicare Supplement to protect seniors and ensure
that the state maintains the ability to regulate this product. [S. Health]
AB 1268 (Rodriguez), as introduced on February 21, 2019, would amend sections 1363.5
and 1367.01 of the Health and Safety Code, to require a health care service plan that prospectively
reviews and approves, modifies, delays, or denies services, based in whole or in part on medical
necessity, to report to DMHC the number of times in the previous year the service was approved,
modified, delayed, or denied. According to the author, “we cannot begin to address the problem
[prior authorizations delaying necessary medical care] without information and facts, and this bill
will ensure that the detailed data is collected and made available to stakeholders .…” [A. Health]
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SB 260 (Hurtado), as amended on March 26, 2019, would amend section 1366.50 of the
Health and Safety Code, relating to automatic health care coverage enrollment. Amended section
1366.50 would require, no later than July 1, 2020, Covered California to use specified information
to enroll an individual who was terminated from a health coverage program administered by the
Department of Health Care Services, in the lowest cost silver plan available, or in the individual’s
previous managed care plan before the termination date of Medi-Cal coverage, under specified
circumstances. This bill would further require a health plan to annually notify an enrollee that
when the enrollee terminates coverage that their contact information will be provided to Covered
California to assist in obtaining other coverage, or that they may opt out of this transfer of
information. [S. Appr]
AB 1656 (Gallagher), as amended on March 21, 2019, would amend section 11217 of the
Health and Safety Code, to clarify that a physician or authorized hospital staff may administer or
dispense controlled substances in a hospital to maintain or detoxify a person related to medical or
surgical treatment of conditions other than addiction, or to treat people with pain for which a
significant relief or cure has not been possible after reasonable efforts. [A. Health]
AB 290 (Wood), as amended on March 5, 2019, would add section 1367.016 to the Health
and Safety Code, to institute requirements for third-party payments of health insurance premiums,
and implement a prohibition on assistance that is conditioned on the use of a specific facility or
provider. New section 1367.016 would require that third-party payers disclose payments to health
plans and requires health plans to report this information to DMHC. According to the author, this
bill addresses concerns that dialysis companies, through a third party, may be veering patients
away from Medicare or Medi-Cal by indirectly paying a patient’s premiums, for the company’s
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own financial benefit. This bill will still allow providers, like dialysis companies, to donate to
nonprofit organizations if they want to help provide premium assistance to patients. [A. Appr]
AB 648 (Nazarian), as amended on March 28, 2019, would add section 1367.13 to the
Health and Safety Code, to establish rules that govern wellness programs instituted by health plans.
New section 1357.13 would require a health plan to comply with data privacy protections, limit
sharing of data and destroy data upon conclusion of the program, and provide clear written
explanations about program parameters, data collection, and enrollee rights. [A. Appr]
AB 1676 (Maienschein), as introduced on February 22, 2019, would add 1367.626 to the
Health and Safety Code, to require that health plans and insurers, by January 1, 2021, establish a
telehealth consultation program and maintain records surrounding certain patient’s telehealth
mental health data. The bill requires a health plan or insurer to communicate information relating
to the telehealth program and its availability to contracting medical providers who treat children
and pregnant and postpartum persons, including pediatricians, obstetricians, and primary care
providers, at least twice a year in writing. [A. Health]
SB 746 (Bates), as introduced on February 22, 2019, would add 1367.667 to the Health
and Safety Code, to require every health plan contract and health insurance policy issued,
amended, or renewed in California on or after January 1, 2020, that provides coverage for
chemotherapy or radiation therapy for the treatment of cancer, to also provide coverage for
anticancer medical devices. [S. Health]
AB 993 (Nazarian), as amended on April 11, 2019, would add 1367.693 to the Health and
Safety Code, to require that if the HIV specialist meets the plan’s criteria, then the health plan must
allow an HIV specialist who is a physician, physician assistant, or nurse practitioner to be eligible
as a primary care provider. According to the author, “Californians living with HIV should have
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access to care from physicians and other providers with the training and experience required to
meet their complex needs.” [A. Appr]
AB 598 (Bloom), as introduced on February 14, 2019, would add 1367.72 to the Health
and Safety Code, to require a health plan to include overage for hearing aids for an enrollee who
is under the age of 18 years. [A. Health]
SB 382 (Nielsen and Stern), as amended on March 26, 2019, would add section 1368.7 to
the Health and Safety Code, to require a health care service plan contract or health insurance policy
entered into, amended, or renewed on or after January 1, 2020, to provide reimbursement for care
provided to enrollees who remain in acute care hospitals, and no longer meet the medical necessity
criteria for care in an acute care hospital, due to a lack of access to post-acute care services during
a state of emergency. This bill would require daily reimbursement rates to be no lower than the
Medi-Cal administrative day rate, unless the plan or insurer has otherwise contracted with the acute
care hospital for reimbursement during a state of emergency. According to the author, “[i]n order
to avoid leaving patients in limbo regarding their health care coverage and questions about access
during an emergency, this bill would ensure that individuals and families with health insurance
can access health care regardless of availability of services outside of an acute care facility.” [S.
Health]

LITIGATION
Pharmaceutical Research & Manufacturers of America v. Brown, Case No. 2:17-cv02573-MCE-KJN (E.D. Cal.). On October 26, 2018, on the Court’s own motion and pursuant to
Local Rule 230(g), U.S. District Judge Morrison C. England, Jr. of the Eastern District of
California vacated the December 13, 2018, hearing on Defendant’s Motion to Dismiss without
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appearance and argument. (This case involves the constitutionality of SB 17 (Hernandez) (Chapter
603, Statutes of 2017), a bill challenged by Petitioner PhRMA in this lawsuit, which attempts to
provide transparency in regard to prescription drug pricing, including requiring drug
manufacturers to provide advance information on and a justification for prescription drug price
increases.) The order also provided that the opposition or statement of non-opposition and reply
shall be filed in accordance with the original motion hearing date and, if the court determines that
oral argument is needed, it will be scheduled at a later date. To date, oral argument has not been
scheduled. At this writing, motions and responses have been submitted by both parties and are
pending.
As reported previously, on September 28, 2018, Petitioner PhRMA submitted its first
amended complaint. PhRMA alleges that SB 17 is unconstitutional in that it compels them to speak
about potential price increases when they would prefer not to communicate that information (thus
violating these corporation’s asserted first amendment rights); additionally, PhRMA alleges that
the bill interferes with interstate commerce. In its prayer for relief, PhRMA seeks an injunction to
prevent California from implementing and enforcing SB 17, and a declaration that the statute is
unconstitutional. [24:1 CRLR 44–45]
Other pharmaceutical companies have followed PhRMA’s lead and filed lawsuits to
prevent the enforcement of SB 17. On December 11, 2018, Petitioner Amgen Inc., filed a Petition
for Writ of Mandate and declaratory and injunctive relief in superior court to prevent disclosure of
its confidential, proprietary, and trade secret drug pricing information that it was required to
provide to the California Correctional Health Care Services (CCHCS) in Amgen Inc. v. The
California Correctional Health Care Services, No. 18STCP03147 (Super. Ct. Los Angeles).
According to the petition, in November and December 2018, CCHCS, informed Amgen that it had
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received Californian Public Records Act (CPRA) requests for the potential price changes that
Amgen had provided to the agency. According to Amgen’s petition, SB 17 does not require drug
manufacturers to publicly disclose potential increases in drug prices, nor does it modify the CPRA
in any way.
On February 1, 2019, after consideration of the parties’ briefs and argument, in an eightpage order (the “PI Order”), the court granted Amgen’s preliminary injunction motion and ordered
that Amgen’s SB 17 notice should not be disclosed pursuant to a CPRA request until Petitioner
effectuates a price increase for the medications in the notice. At this writing, Defendant CCHCS’s
appeal is pending.
A similar ruling was also granted in Ipsen Biopharmaceuticals, Inc. v. California Public
Employees’ Retirement System, et al., No. CPF-18-516445 (Super. Ct. San Francisco). On
December 13, 2018, the superior court judge granted Ipsen Biopharmaceuticals, Inc.’s order to
show cause and temporary restraining order against defendants The California Public Employees’
Retirement System (CalPERS), and the California Correctional Health Care Services (CCHCS).
CalPERS and CCHCS are ordered to show cause why a preliminary injunction should not be
ordered, pending trial in this action, restraining and enjoining defendants from disclosing the
content of any Ipsen confidential pricing information submitted in accordance with the section
127677 of the Health and Safety Code, as responsive to the CPRA request received or to be
received requesting such information.
On February 27, 2019, the court issued an order on joint stipulation regarding stay of
proceedings in this action. The court stated that there is “substantial overlap between the claims,
issues, and parties involved in this case and the Los Angeles litigation (Amgen Inc. v. The
California Correctional Health Care Services); and therefore, the outcome of proceedings relating

California Regulatory Law Reporter ♦ Volume 24, No. 2 (Spring 2019) ♦
Covers October 16, 2018 – April 15, 2019

37

to the preliminary injunction motion in the Los Angeles case will affect the scope and conduct of
this case. According to the order, the parties stipulate and agree that all proceedings in this
litigation shall be stayed while the preliminary injunction in the Los Angeles litigation remains in
effect and the stay will automatically expire if the preliminary injunction in the Los Angeles
litigation is terminated. The order also stipulates, in the event that an order issued terminates the
preliminary injunction in the Los Angeles litigation, CalPERS and CCHCS shall continue to
withhold Ipsen’s allegedly confidential and proprietary information for a period of 21 days from
the issuance of the order. If Ipsen moves for a preliminary injunction during that 21-day period,
CalPERS and CCHCS shall continue to withhold Ipsen’s allegedly confidential and proprietary
information until a ruling on that motion is issued.
Not all parties requesting preliminary injunctions against agencies are being granted so
quickly. On October 26, 2018, the Plaintiffs’ motion for preliminary injunction was heard and
taken under advisement in Association for Community Affiliated Plans, et al. v. United States
Department of Treasury, et al., Case No. 1:18-cv-02133-RJL (D.D.C.). The court stated that it
would not be possible to complete an opinion in this case within a few weeks because it’s too
complicated, too large, and too consequential, and then the court went into recess.
On November 12, 2018, upon consideration of Plaintiffs’ notice of withdrawal of motion
for a preliminary injunction and motion for expedited briefing schedule, and defendants’ response,
the court ordered a hearing on the parties’ cross-motions for summary judgment to be held on
February 19, 2019. However, on December 31, 2018, Judge Richard J. Leon granted the
Defendants’ motion to stay proceedings in light of a lapse of appropriations to the Department of
Justice. On March 1, 2019, Judge Leon ordered that the stay in this case be lifted and Defendants’
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motion to modify the briefing schedule be granted. At this writing, all parties and numerous amici
curiae are briefing the case; no further arguments have been held.

Update on Federal Government Actions
♦ Texas, et al. v. United States of America, 300 F. Supp. 3d 810 (2019). In Texas v. United
States of America, twenty Republican state attorneys general and two individual plaintiffs
challenged the constitutionality of the individual mandate and with it, the entire Affordable Care
Act (ACA). The states brought an action alleging that the United States, United States Department
of Health and Human Services (HHS), HHS Secretary, Internal Revenue Service (IRS), and its
Commissioner, effectively required states to pay Health Insurance Providers Fees (HIPF) imposed
by the ACA in order to receive Medicaid funds, thus, violated the vesting clause, the
Administrative Procedure Act (APA), and the spending clause. Plaintiffs sought declaratory
judgment and a permanent injunction to prevent the defendants from prospectively collecting the
provider fees. The parties in the action filed cross-motions for summary judgment.
On March 5, 2019, Judge Reed O’Connor held that the ACA is unconstitutional. The ruling
is currently being appealed and several stakeholders have been filing amicus briefs during the past
several months, including The National Women’s Law Center, National Partnership for Women
and Families, and the Black Women’s Health Initiative.
♦ State of New York, et al. v. U.S. Department of Labor, Civ. Action No. 18-1747,
(D.D.C.). The following is a status update on State of New York, et al. v. U.S. Department of Labor
has been covered previously in Volume 24, No. 1 (Fall 2018) of the California Regulatory Law

Reporter [24:1 CRLR 46]:

California Regulatory Law Reporter ♦ Volume 24, No. 2 (Spring 2019) ♦
Covers October 16, 2018 – April 15, 2019

39

On March 28, 2019, United States District Judge Bates entered an order granting the
motion for summary judgment for the plaintiff and denying motion for summary judgement and
motion to dismiss for the defendant. On August 23, 2018, Plaintiffs filed a memorandum of law in
support of a motion for summary for judgment. Plaintiffs argue that the administration is violating
the ACA’s purpose of establishing minimum insurance protections. Defendants filed a counter
memorandum of law in support of their position for summary judgment in conjunction with a
motion to dismiss. In defendant’s memorandum for summary judgement it is argued that loosening
of health plans allows for more affordable health care, and more covered Americans.
On July 26, 2018, the complaint was filed by 12 state attorneys general entitled State of
New York, et al. v. U.S. Department of Labor, in the U.S. District Court for the District of
Columbia. This complaint challenges the Trump administration’s regulation issued this year that
makes it easier for individuals and small employers to band together to purchase health care
coverage through association health plans (AHPs) that do not meet ACA standards.
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